Anti‐endotoxin immunotherapy for canine parvovirus endotoxaemia

Abstract

AbstractThe morbidity and mortality associated with canine parvovirus disease (CPV) is caused, in part, by endotoxin (LPS). Equine anti‐endotoxin hyperimmune plasma (Anti‐LPS) was administered to 89 CPV patients in addition to conventional therapy. In Anti‐LPS treated CPV patients mortality was lower (16‐8 per cent, 15/89) than in controls that received conventional therapy alone (66‐7 per cent, 24/36, P < 0–0005). The hospitalization period of survivors was reduced from 8‐5 ± 4‐0 days (controls) to 5‐2 ± 2‐0 days (Anti‐LPS treated group). These results suggest that an anti‐endotoxin specific therapy should be incorporated into the treatment regimen of CPV, and possibly, other canine enteric disorders, known to produce endotoxaemia.